"Plasmodium falciparum" histidine-rich protein 2 (PfHRP2) diversity in Ghana

CURRENT STATUS: UNDER REVIEW

Othere Addai-Mensah
Kwame Nkrumah University of Science and Technology College of Health Sciences

Bismarck Dinko
University of Health and Allied Sciences

Mark Noagbe
Kwame Nkrumah University of Science and Technology

Selassie Louis Ameke
Ho Municipal Hospital

Max Efui Annani-Akollor
Kwame Nkrumah University of Science and Technology

Eddie-Williams Owiredu
Kwame Nkrumah University of Science and Technology

Kofi Mensah
Kwame Nkrumah University of Science and Technology

Richmond Tackie
University of Health and Allied Sciences

Eliezer Togbe
Kwame Nkrumah University of Science and Technology

Comfort Agyare-Kwabbi
University of Health and Allied Sciences

Charles Gyasi
Kwame Nkrumah University of Science and Technology

Constance Adu-Gyamfi
SUBJECT AREAS
Infectious Diseases

KEYWORDS
Malaria, Plasmodium falciparum, histidine-rich protein 2, Rapid diagnostic test, Ghana
Abstract

**Background:** In the absence of microscopy, *Plasmodium falciparum* histidine-rich proteins 2 (PfHRP2)-based rapid diagnostic tests (RDTs) are recommended for the diagnosis of falciparum malaria, particularly in endemic regions. However, genetic variability of the PfHRP2 gene threatens the usefulness of the test. This study aimed to investigate the diversity of PfHRP2 in malaria cases among children in Ghana.

**Methods:** A cross-sectional study was conducted at the Adidome Government Hospital in the Volta Region of Ghana. A total of 50 children with mean age of 6.6±3.5 years and diagnosed of falciparum malaria were included. Blood samples were collected for complete blood count, malaria parasite identification and counting. DNA samples were amplified and sequenced. Nucleotide sequences were translated *in silico* to corresponding amino acids and the deduced amino acids sequences were analyzed for diversity.

**Results:** The number of repeats and number of each repeat within PfHRP2 varied between isolates. Twelve rare PfHRP2 repeat types, two of which are previously unreported, were identified in this study. Our HRP2 sequence shared high similarity with isolates from Kenya. Using Baker’s regression model, Group B was the highest occurring type (58.0%). Screening of all sequences for epitopes recognized by PfHRP2-specific monoclonal antibodies (mAbs), we found the predominant motif to be AHHAADAH, which is recognized by the C1-13 mAbs.

**Conclusion:** This study reports diversity of *P. falciparum* histidine-rich proteins 2 in samples from Ghanaian children with symptomatic malaria. We highlight the existence of extra amino acid repeat types which adds to the PfHRP2 antigenic variability. The findings of this study will contribute to the understanding of the performance of PfHRP2-based RDTs in the Ghanaian setting.

**Introduction**

Malaria, which causes substantial morbidity and mortality, is a major public health problem in sub-Saharan Africa, Asia, and Latin America [1]. It claims the life of a child under five years every two minutes in sub-Saharan Africa and has annual infection and mortality rates of 191 million and 395,000 individuals, respectively [2, 3]. In Ghana, malaria remains a major cause of loss of days of healthy life,
accounting for not less than 20% of child deaths, 40% of child hospital admissions, and more than 50% of outpatient attendances [4-7].

Although, microscopic examination of stained blood smears remains the gold standard for malaria diagnosis, its benefit is limited by the absence of adequate skilled personnel, and infrastructural and logistic resources, particularly in resource-poor areas [8]. To overcome this problem, the World Health Organization (WHO) included rapid diagnostic tests (RDTs), a relatively less expensive and easily accessible test, as one of the alternative testing systems for malaria diagnosis prior to the prescription of antimalarial drugs.

Since its development in the 1990s, and with more than 200 currently available brands, there has been consistent reports of observable increase in malaria RDT sales worldwide [9, 10]. Most of the malaria RDTs exploit the presence of P. falciparum Histidine-Rich Protein-2 (PfHRP2) for the detection of Plasmodium falciparum [11]. The presence of repetitive epitopes, that enable their detection by multiple antibodies, and their abundance in blood during the blood-stage of malaria infections has made the PfHRP2 protein a common antigenic target for RDTs [12, 13].

In 2010, Ghana implemented the test-before-treat guideline for malaria where RDT use was promoted to facilitate diagnosis [14]. However, aside low parasite levels especially in asymptomatic cases, improper interpretation of RDT results and/or the handling and storage of RDT kits, deletion of the PfHRP2 gene and extensive antigen diversity has contributed to discrepancies in the RDT sensitivity [15-20], threatening the future use of the test method, particularly in malaria-endemic regions such as Ghana. Indeed, a recent study in Ghana reported PfHRP2 gene deletion in 33% and 36% of microscopically-confirmed and PCR-confirmed RDT positive samples, respectively [21]. Over the past decade, several countries, especially in Africa, have reported cases of P. falciparum isolates with deleted PfHRP2, and isolates with high PfHRP2 diversity [15-20, 22, 23], with potential negative implications for malaria control and elimination programs. These notwithstanding, studies on PfHRP2 gene deletion and diversity of the PfHRP2 gene in Ghana, a malaria endemic country, are lacking. This study thus aimed to investigate the diversity of PfHRP2 in malaria cases among children in Ghana.
Materials And Methods

Study design/setting and participants

A cross-sectional study was conducted between January and June 2019 at the Adidome Government Hospital in the Volta Region of Ghana. The Volta Region has a perennial malaria transmission, with the predominant parasite being *P. falciparum*. The regional prevalence of *P. falciparum* malaria is 45.27% among children [24]. In the study, 50 children between the ages of 3-11 diagnosed of *falciparum* malaria were included. Samples were obtained prior to initiation of antimalarial therapy.

Sample collection and laboratory analysis

Three milliliters (3 ml) of blood was aseptically obtained from each participant and dispensed into K3 EDTA tubes. Complete blood count was performed on the anticoagulated whole blood using Sysmex KX-21N auto analyzer (Sysmex Corporation, Japan). To reassess falciparum malaria, thick and thin blood films were prepared and stained with 10% Giemsa for microscopic identification and counting of parasites. The parasite density was calculated by assuming a standard WBC count of 8000/μl or 4.5 million RBC/μl in accordance with WHO standards [25]. Additionally, 5 drops of the blood were spotted onto Whatman™ Filter Papers (Schleicher and Schuell BioScience, Inc., Keene, New Hampshire), air dried and individually kept in zip-lock plastic bag for subsequent PCR analysis.

Parasite DNA extraction and molecular analysis

DNA isolation from Whatman filter papers was based on the Chelex-based technique as previously described [26]. PCR amplification of the exon 2 of the PfHRP2 gene was performed using the semi-nested amplification approach as previously described by Baker et al. [16]. PCR reactions were carried out in 25μl volume for the primary and 35μl volume for the semi-nested reactions. The forward and reverse primers targeting the exon 2 of the pfhrp2 gene are shown in Additional file 1: Table S1. For both primary and secondary PCR reactions, DNA was denatured at 96°C for 10 minutes followed by 40 cycles of denaturation at 95°C for 50 seconds, annealing at 55°C for 50 seconds, extension at 68°C for 1 minute and a final extension at 72°C for 5 minutes. Genomic DNA from 3D7 (wild type) *P. falciparum* and nuclease free water were used as positive and negative controls,
respectively. After secondary amplification, amplicons were separated by electrophoresis on 2% agarose gels, stained with ethidium bromide and visualized under UV light. Sequencing of the PfHRP2 gene was performed by Inqaba Biotechnical Industries (Pty) Ltd, South Africa (https://www.inqababiotec.co.za/). Nucleic acid sequences were deposited at the National Center for Biotechnology Information (NCBI) (Genbank accession numbers: MT094447-79)

Data analysis

Mega X version 10.1.6 [27] was used for sequence analysis. Nucleotide sequences were translated in silico to corresponding amino acids using the correct open reading frame. Amino acid repeats were numerically coded based on previous reports [16, 18, 28]; the frequencies and percentages of each amino acid repeat were estimated. To compare amino acid sequences in this study with previously published data, we performed a protein-protein BLAST (BLASTP) analysis of our sequences with those in the GenBank database at the NCBI. Our PfHRP2 and homologous sequences downloaded from the NCBI were aligned using the ClustalW tool and a cladogram was built using the Maximum Likelihood method and Dayhoff matrix-based model, with bootstrap consensus tree inferred from 1000 replicates. Although rapid diagnostic tests (RDTs) results were unavailable, we sought to determine the diversity of PfHRP2 with respect to RDT sensitivity. To achieve this, the product of repeats type 2 and 7 was calculated; classification and interpretation was based on Baker’s regression model [16]. Screening of our sequences for epitopes recognized by PfHRP2-specific monoclonal antibodies (mAbs) [29] were also performed.

Results

A total of 50 children with mean age of 6.6±3.5 years were included. There were more females than males (56.0% vs 44.0%). The average red blood cell count, hemoglobin, hematocrit, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, white blood cell count, platelet count and parasite density were 4.0±0.7 x10^6/µL, 10.5±1.6 g/dL, 30.8±4.6 %, 77.2±6.4 fL, 26.7±4.1 pg, 34.5±3.7 g/dL, 7.5±2.7 x10^3/µL, 101.0 (63.0-171.3) x10^3/µL and 35411.0 (15183.9-65280.7)/µL, respectively (Table 1).

Thirty-three different PfHRP2 amino acid sequences were identified among 50 PfHRP2 sequences
obtained in this study. The size of PfHRP2 ranged from 225 to 304 amino acids among all isolates and 25 to 38 amino acid repeat types per isolate. The total number of repeats and the number of each repeat within PfHRP2 varied between isolates. Repeat types 2, 6, 7 and 8 were observed in 100% of the isolates. Repeat types 5 and 12 were observed in 98% whereas types 1, 3 and 10 were found in 92-96% of the samples. The repeat types 4 and 13 occurred in 26% and 10% of the isolates, respectively. None of the samples had repeat types 9 and 11 (Table 2).

Twelve rare PfHRP2 repeat types, two of which are previously unreported, were identified in this study; the two were APDAHHVAD and AHHAAAHDEAAALI. Of the rare repeat types, types 2 (AHHAHAAAH) and 7 (AHHAAAH) had the highest frequency (Table 3).

Predominant repeat types in this study were used to model the structural organization of PfHRP2 in Ghana. Although the structural organization of the PfHRP2 repeat types was variable, the repetitive regions found in most of our samples started with type 1 (94.0%) and all PfHRP2 sequences terminated with type 12 (100.0%) (Fig. 1a). Fifty-four percent of our isolates had a semi-conserved PfHRP2 repeat type motif composed of repeat types 2, 3, 5, 7, 8, 2 and 7. Partial amino acid repeat motif comprising types 7, 8, 2 and 7 was found in 34.0% of the isolates.

To explore the similarities between the modelled PfHRP2 sequence obtained from the Ghanaian isolates and those from other regions available at the NCBI, we performed BLASTP analysis of our amino acid sequence. Seven hits (Accession numbers: QBC65525.1, QBC65570.1, QBC65591.1, QBC65640.1, QBC65657.1 and QBC65674.1 from isolates in Kenya and AKO62989.1 from China-Myanmar border area) were obtained (Fig. 1b; Additional file 1: Table S2). Our modelled HRP2 sequence shared 85-94% similarity with Kenyan isolates and 94% similarity with the isolates from China-Myanmar border area. BLASTP of the sequences from each of the 50 samples revealed that 78.0% (39/50) have high similarities with isolates from Kenya, highlighting possible shared identity between PfHRP2 from Ghana and Kenya (Additional file 1: Table S3).

Although data on rapid diagnostic tests (RDTs) was unavailable, an obvious limitation of the study, we employed the Baker model [16] to determine the distribution on the basis of PfHRP2 diversity with respect to RDT sensitivity. Isolates were classified as Groups A, B, I and C if their Baker repeat (type 2
× type 7) was >100, 50-100, 44-49 and < 43, respectively. Group B was the highest occurring type (58.0%), followed by group C (22.0%) (Table 4).

Due to the relatively high percentage of group C isolates (22.0%), which have been reported to be associated with RDT non-sensitivity [30] obtained in this study, we explored the distribution of possible epitopes to be targeted by mAb RDTs based on the study by Lee et al. [29]. The predominant motif among the 50 isolates was AHHAADAHH which is recognized by the C1-13 mAb, followed by AHHAHHA, recognized by mAb 3A4. None of our isolates had the AYAHHAHHAAY motif, while the HAHHAHHAADAHH motif, recognized by C2-3, occurred at a lower frequency (Table 5).

Discussion

In Africa, P. falciparum is the most common malaria-causing parasite. Microscopy is the gold standard for the diagnosis of malaria, however, in the its absence, RDT has been approved by the WHO for use in malaria diagnosis. Majority of the commercially available RDTs target the PfHRP2; however, the future benefit of these RDTs is in jeopardy due to reports of P. falciparum isolates which lack the PfHRP2 gene [15-19, 22, 23]. It is thus of public health significance to assess the diversity of the PfHRP2, especially in different parts of Africa where the disease exerts a high rate of morbidity and mortality, particularly among children.

Here, we present an analysis of the diversity of PfHRP2 among P. falciparum isolates from children in Ghana. To the best of our knowledge, this is the first study to present data on the diversity of PfHRP2 in the Ghanaian context. In contrast with a study by Amoah et al. in Ghana who reported PfHRP2 gene deletion in 33% and 36% of the microscopically-confirmed and PCR-confirmed RDT positive samples, respectively [21], all our isolates achieved successful sequencing of the PfHRP2 gene indicating absence of deletion. This finding is in harmony with studies by Baker et al. [16, 20] and Nderu et al. [18]. Compared with the study by Amoah et al., which was conducted in the Coastal parts of Ghana, the lack of PfHRP2 gene deletion in our study (conducted in the middle belt) suggests that geographical differences could play a role in PfHRP2 gene diversity. Studies in other regions of the country are thus warranted. It should also be noted, however, that inclusion of only symptomatic malaria cases and the limited sample size may have influenced our findings. A larger sample size is
recommended in future studies.

After *in silico* translation of the PfHRP2 genes into amino acid sequences, our isolates shared some characteristics with previous published data. Repeat types 2, 6, 7 and 8 were found in all isolates whereas types 9 and 11 were absent. Few of our isolates had the type 4 repeat and only 10% had the type 12. All other repeat types were found in over 90% of the isolates. These findings are consistent with previous reports from other countries [18, 20, 28, 30-32].

We found the structural organization of repeat types to be highly diverse. Out of the 33 unique PfHRP2 sequences obtained, only a third occurred more than once. However, some repeat organizations were shared between isolates. Most of our sequences started with type 1 and all terminated with type 12 as is consistent with previous studies [18-20, 28]. Additionally, a semi-conserved PfHRP2 repeat type motif (types 2, 3, 5, 7, 8, 2 and 7) and partial repeat motif (types 7, 8, 2 and 7) were found in about half and a quarter of our isolates, respectively. This is similar to the findings of Baker et al. [20] and Nderu et al. [18]. Phylogenetic analysis of the Ghana PfHRP2 revealed striking similarities with isolates from Kenya. In a study along the Chinese-Myanmar border, novel PfHRP2 repeat types arising from replacement of a single amino acid of eight amino acid repeats types were identified [33]. Nderu et al. [18] also found 39 novel PfHRP2 repeat types. In India, Bharti et al. reported 5 novel repeat types [19]. In this study, we identified two novel PfHRP2 repeat types (APDAHHVAD and AHHAAHDEAAALI) in addition to ten of the recently reported novel repeats which occurred at low frequencies. Together with previous reports, our findings support the presence of yet to be defined repeat types and highlights that these novel types occur at relatively lower frequencies. PfHRP2 diversity has been reported to influence the diagnosis of malaria using PfHRP2-based RDTs. In 2005, Baker et al. demonstrated, using logistic regression model, that the product of repeat types 2 and 7 affect inter-study sensitivity variation of PfHRP2-based RDTs, especially for samples with parasite densities ≤ 250 parasites/μL [16]. In 2010 however it was found, using isolates from different geographical areas, that type 2 × type 7 was not associated with RDT sensitivity [20]. Nonetheless, subsequent studies by Kumar et al. [30] in 2012 and Wurtz et al. [34] in 2013 observed an association between the Group C category (type 2 × 7 < 43) and RDT false negativity and reduced limit of
detection. Most of our isolates were group B (type 2 × 7 = 50-100) as consistent with previous studies in Africa [18, 35, 36]. To investigate the distribution of possible epitopes to be targeted by monoclonal antibodies in RDTs, we searched for the eleven common epitopes recognized by commercially available mAb [29] among our isolates. The most occurring epitope was AHHAADAHH, recognized by the C1-13 mAb, followed by AHHAHHA, recognized by mAb 3A4. We did not detect the AYAHHAHAAY motif in our isolates and HAHHAHHAADAHH occurred at a lower frequency. This is consistent with recent reports by Fontecha et al. [28] and Willie et al. [37] and corroborates with an earlier report by Lee et al. that RDTs which employ the C2-3 and Genway mAbs are less sensitive [29].

Conclusion

This study reports diversity of *Plasmodium falciparum* histidine-rich proteins 2 in samples from Ghanaian children with symptomatic malaria. Additionally, we highlight the existence of extra amino acid repeat types which adds to the PfHRP2 antigenic variability. The findings of this study will contribute to the understanding of the performance of PfHRP2-based RDTs in the Ghanaian setting.

Abbreviations

PfHRP2: Plasmodium falciparum histidine-rich proteins 2

WHO: World Health Organization

RDT: rapid diagnostic test

PCR: polymerase chain reaction

BLAST: Basic Local Alignment Search Tool

mAb: monoclonal antibodies

Declarations

**Ethics approval and consent to participate**

The study was approved by the Committee on Human Research, Publications and Ethics (CHRPE/AP/606/19) of the School of Medical Sciences at Kwame Nkrumah University of Science and Technology. Written consent was obtained from parents and guardians of the children after the objectives of the study had been explained to them.

**Consent for publication**
Not applicable.

**Availability of data and material**

The datasets supporting the conclusions of this article are included within the article and its additional file.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Authors’ contribution**

OAM conceived the idea for the study. OAM and AYD supervised the research. OAM, BD, MN, SLA, MEAA, EWO, KM, RT, ET, CAK, CG, CAG and AYD contributed with the design of the study, collection of data and laboratory analysis. EWO analyzed, interpreted the data and drafted the paper. OAM, MEAA and EWO revised the paper. All authors read and approved the final manuscript.

**Acknowledgements**

The authors are grateful to the Staff of the Adidome Government Hospital and all who actively participated in the study.

**Additional file 1:** Primers used, BLASTP hits for HRP2 sequence modelled from Ghanaian isolates and BLASTP of Ghanaian HRP2 sequences for all 50 samples.

**References**

1. WHO. World malaria report 2018 Geneva: World Health Organization; 2018. Available from: https://www.who.int/malaria/publications/world-malaria-report-2018/en/.

2. WHO. World Malaria Report 2019 Geneva: World Health Organization; 2019. Available from: https://www.who.int/news-room/feature-stories/detail/world-malaria-report-2019.

3. Addai-Mensah O, Annani-Akollor ME, Fondjo LA, Anto EO, Gyamfi D, Sallah L, et al. High-Sensitivity C-Reactive Protein: A Potential Ancillary Biomarker for Malaria
Diagnosis and Morbidity. Disease Markers. 2019;2019:7. doi: 10.1155/2019/1408031.

4. Owusu-Agyei S, Asante K, Adjuik M, Adjei G, Awini E, Adams M. Epidemiology of malaria in the forest-savanna transitional zone of Ghana. Malaria Journal. 2009;8(1):1.

5. Sarpong N, Owusu-Dabo E, Kreuels B, Fobil J, Segbaya S, Amoyaw F, et al. Prevalence of malaria parasitaemia in school children from two districts of Ghana earmarked for indoor residual spraying: A cross-sectional study. Malaria Journal. 2015;14:260. doi: 10.1186/s12936-015-0772-6.

6. Addai-Mensah O, Annani-Akollor M, Fondjo L, Sarbeng K, Anto E, Owiredu E, et al. Regular Antenatal Attendance and Education Influence the Uptake of Intermittent Preventive Treatment of Malaria in Pregnancy: A Cross-Sectional Study at the University Hospital, Kumasi, Ghana. J Journal of tropical medicine. 2018;2018.

7. Initiative PM. Malaria Operational Plan Report Ghana. 2018.

8. Wongsrichanalai C, Barcus MJ, Muth S, Sutamihardja A, Wernsdorfer WH. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). The American journal of tropical medicine and hygiene. 2007;77(6_Suppl):119-27.

9. Incardona S, Serra-Casas E, Champouillon N, Nsanzabana C, Cunningham J, González IJ. Global survey of malaria rapid diagnostic test (RDT) sales, procurement and lot verification practices: assessing the use of the WHO–FIND Malaria RDT Evaluation Programme (2011–2014). Malaria journal. 2017;16(1):196.

10. Cunningham J, Jones S, Gatton ML, Barnwell JW, Cheng Q, Chiodini PL, et al. A review of the WHO malaria rapid diagnostic test product testing programme (2008–2018): performance, procurement and policy. Malaria Journal. 2019;18(1):387.

11. Ugah UI, Alo MN, Owolabi JO, Okata-Nwali OD, Ekejindu IM, Ibeh N, et al. Evaluation of the utility value of three diagnostic methods in the detection of malaria parasites
in endemic area. Malaria journal. 2017;16(1):189.

12. Moody A. Rapid diagnostic tests for malaria parasites. Clinical microbiology reviews. 2002;15(1):66-78.

13. Panton LJ, McPhie P, Maloy WL, Wellems TE, Taylor DW, Howard RJ. Purification and partial characterization of an unusual protein of Plasmodium falciparum: histidine-rich protein II. Molecular and biochemical parasitology. 1989;35(2):149-60.

14. Boadu NY, Amuasi J, Ansong D, Einsiedel E, Menon D, Yanow SK. Challenges with implementing malaria rapid diagnostic tests at primary care facilities in a Ghanaian district: a qualitative study. Malaria journal. 2016;15(1):126.

15. Gamboa D, Ho M-F, Bendezu J, Torres K, Chiodini PL, Barnwell JW, et al. A large proportion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PloS one. 2010;5(1).

16. Baker J, McCarthy J, Gatton M, Kyle DE, Belizario V, Luchavez J, et al. Genetic diversity of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of PfHRP2-based rapid diagnostic tests. The Journal of infectious diseases. 2005;192(5):870-7.

17. Beshir KB, Sepúlveda N, Bharmal J, Robinson A, Mwangui J, Busula AO, et al. Plasmodium falciparum parasites with histidine-rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya. Scientific reports. 2017;7(1):1-10.

18. Nderu D, Kimani F, Thiong’o K, Karanja E, Akinyi M, Too E, et al. Plasmodium falciparum histidine-rich protein (PfHRP2 and 3) diversity in Western and Coastal Kenya. Scientific reports. 2019;9(1):1-9.

19. Bharti PK, Chandel HS, Krishna S, Nema S, Ahmad A, Udhayakumar V, et al. Sequence variation in Plasmodium falciparum histidine rich proteins 2 and 3 in Indian isolates: implications for malaria rapid diagnostic test performance. Scientific reports.
20. Baker J, Ho M-F, Pelecanos A, Gatton M, Chen N, Abdullah S, et al. Global sequence variation in the histidine-rich proteins 2 and 3 of Plasmodium falciparum: implications for the performance of malaria rapid diagnostic tests. Malaria journal. 2010;9(1):129.

21. Amoah LE, Abankwa J, Oppong A. Plasmodium falciparum histidine rich protein-2 diversity and the implications for PfHRP 2: based malaria rapid diagnostic tests in Ghana. Malaria journal. 2016;15(1):101.

22. Parr JB, Verity R, Doctor SM, Janko M, Carey-Ewend K, Turman BJ, et al. Pfhrp2-deleted Plasmodium falciparum parasites in the Democratic Republic of the Congo: a national cross-sectional survey. The Journal of infectious diseases. 2017;216(1):36-44.

23. Menegon M, L'Episcopia M, Nurahmed AM, Talha AA, Nour BY, Severini C. Identification of Plasmodium falciparum isolates lacking histidine-rich protein 2 and 3 in Eritrea. Infection, Genetics and Evolution. 2017;55:131-4.

24. Verner O, Kokou AA, Jones O-A, James O-Y, Ibrahim J, Innocent A, et al. Asymptomatic Plasmodium falciparum infection and poor school performance in primary school children in the Volta Region of Ghana. Ethiopian journal of health sciences. 2018;28(6).

25. WHO. Basic malaria microscopy – Part I: Learner's guide. Second edition: World Health Organization; 2010. Available from: https://apps.who.int/iris/bitstream/handle/10665/44208/9789241547826_eng.pdf;jsessionid=F5D7D3AA5371D0B562103A5649F372C5?sequence=1.

26. Bereczky S, Mårtensson A, Gil JP, Färnert A. Rapid DNA extraction from archive blood spots on filter paper for genotyping of Plasmodium falciparum. The American journal
of tropical medicine and hygiene. 2005;72(3):249-51.

27. Kumar S, Stecher G, Li M, Knyaz C, Tamura K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Molecular biology and evolution. 2018;35(6):1547-9.

28. Fontecha G, Pinto A, Escobar D, Matamoros G, Ortiz B. Genetic variability of Plasmodium falciparum histidine-rich proteins 2 and 3 in Central America. Malaria journal. 2019;18(1):31.

29. Lee N, Gatton ML, Pelecanos A, Bubb M, Gonzalez I, Bell D, et al. Identification of optimal epitopes for Plasmodium falciparum rapid diagnostic tests that target histidine-rich proteins 2 and 3. Journal of clinical microbiology. 2012;50(4):1397-405.

30. Kumar N, Singh JP, Pande V, Mishra N, Srivastava B, Kapoor R, et al. Genetic variation in histidine rich proteins among Indian Plasmodium falciparum population: possible cause of variable sensitivity of malaria rapid diagnostic tests. Malaria journal. 2012;11(1):298.

31. Atroosh WM, Al-Mekhlafi HM, Al-Jasari A, Sady H, Al-Delaimy AK, Nasr NA, et al. Genetic variation of pfhrp2 in Plasmodium falciparum isolates from Yemen and the performance of HRP2-based malaria rapid diagnostic test. Parasites & vectors. 2015;8(1):388.

32. Deme AB, Park DJ, Bei AK, Sarr O, Badiane AS, Gueye PEHO, et al. Analysis of pfhrp2 genetic diversity in Senegal and implications for use of rapid diagnostic tests. Malaria journal. 2014;13(1):34.

33. Li P, Xing H, Zhao Z, Yang Z, Cao Y, Li W, et al. Genetic diversity of Plasmodium falciparum histidine-rich protein 2 in the China–Myanmar border area. Acta tropica. 2015;152:26-31.

34. Wurtz N, Briolant S, Lemarie D, de Santi Pommier V, Pascual A, Roodt T, et al.
Delayed diagnosis of Plasmodium falciparum in a soldier in Uganda: false-positive rapid diagnostic test associated with reduced repeats in pfhrp2. Medecine et sante tropicales. 2013;23(2):181-4.

35. Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, et al. Pfhrp2 and pfhrp3 polymorphisms in Plasmodium falciparum isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. Malaria journal. 2013;12(1):34.

36. Mariette N, Barnadas C, Bouchier C, Tichit M, Ménard D. Country-wide assessment of the genetic polymorphism in Plasmodium falciparum and Plasmodium vivax antigens detected with rapid diagnostic tests for malaria. Malaria journal. 2008;7(1):219.

37. Willie N, Zimmerman PA, Mehlotra RK. Plasmodium falciparum histidine-rich protein 2 gene variation in a malaria-endemic area of Papua New Guinea. The American journal of tropical medicine and hygiene. 2018;99(3):697-703.

Tables

Table 1. Demographics and hematological profile of the study population.
| Variables                    | Mean±SD        | Min-Max       |
|------------------------------|----------------|---------------|
| Age                          | 6.6±3.5        | 1-14          |
| Sex*                         | n              | %             |
| Female                       | 28             | 56.0          |
| Male                         | 22             | 44.0          |
| RBC (x10⁶/µL)                | 4.0±0.7        | 2.0-5.3       |
| Hb (g/dL)                    | 10.5±1.6       | 6.3-13.7      |
| HCT (%)                      | 30.8±4.6       | 16.1-38.6     |
| MCV (fL)                     | 77.2±6.4       | 62.1-90.8     |
| MCH (pg)                     | 26.7±4.1       | 18.7-45.6     |
| MCHC (g/dL)                  | 34.5±3.7       | 29.9-57.8     |
| WBC (x10³/µL)                | 7.5±2.7        | 2.4-12.8      |
| PLT (x10³/µL)‡               | 101.0 (63.0-171.3) | 20.0-365.0 |
| Parasite density (parasites/µL)‡ | 35411.0 (15183.9-65280.7) | 568.0-1033730.0 |

*Presented as frequencies and percentages; ‡Presented as medians (interquartile ranges). RBC: red blood cell count, Hb: hemoglobin, HCT: hematocrit, MCV: mean cell volume, MCH: mean cell hemoglobin, MCHC: mean cell hemoglobin concentration, WBC: white blood cell count, PLT: platelet count.

**Table 2. Frequencies and proportions of PfHRP2 amino acid repeat types.**
| Code       | Repeat sequences     | Repeat frequency | Repeat percentage |
|------------|----------------------|------------------|-------------------|
| Type 1 motif | AHHAHHVAD            | 142              | 94.0              |
| Type 2 motif | AHHAHHAAD            | 572              | 100.0             |
| Type 3 motif | AHHAHHAAY            | 67               | 92.0              |
| Type 4 motif | AHH                 | 20               | 26.0              |
| Type 5 motif | AHHAHASD            | 58               | 98.0              |
| Type 6 motif | AHHATD             | 178              | 100.0             |
| Type 7 motif | AHHAAD             | 312              | 100.0             |
| Type 8 motif | AHHAAY            | 65               | 100.0             |
| Type 10 motif | AHHAAAHATD      | 74               | 96.0              |
| Type 12 motif | AHHAAAHHEAATH   | 50               | 98.0              |
| Type 13 motif | AHHASD            | 5                | 10.0              |

Table 3. List of rare and novel PfHRP2 amino acid repeat types identified in Ghana.
| Code       | Known repeats       | Rare/novel repeats | Repeat frequency |
|------------|---------------------|--------------------|------------------|
| Type 1 motif | AHHAHHVAD          | AHHAHVVAY         | 3                |
|            |                     | AHHTTHVAD         | 1                |
|            |                     | APDAHVAD          | 1                |
| Type 2 motif | AHHAHHAAD         | AHHAHHAAPD        | 1                |
|            |                     | AHHAHHAADD        | 2                |
|            |                     | AHHAHAAH‡         | 5                |
| Type 5 motif | AHHAHHASD         | AHHAPHASD         | 1                |
| Type 7 motif | AHHAAD             | AHHAH‡             | 6                |
|            |                     | AHHADD             | 1                |
| Type 10 motif | AHHA^AAAHATD     | AHHAA^TTHATD      | 1                |
| Type 12 motif | AHHA^AAAH^HEAATH  | AHHA^AAAHHEAASH   | 3                |
|            |                     | AHHA^AAAH^DEAA^LI* | 1              |

*Previously unidentified repeat. †More than one repeat copies per isolate. Boldened amino acid shows the position where the rare/novel repeat types vary compared to known repeat types.

**Table 4. Frequency of occurrence of PfHRP2 groups (Baker model) in Ghana.**
| Diversity | Frequency | Percentages |
|-----------|-----------|-------------|
| A         | 2         | 4.0         |
| B         | 29        | 58.0        |
| C         | 11        | 22.0        |
| I         | 8         | 16.0        |

Table 5. Distribution of potential epitopes targeted by monoclonal antibodies in RDTs among Ghanaian isolates

| Monoclonal antibody | Epitope motif            | Samples containing motif [n (%)] | Motif per isolate |
|---------------------|--------------------------|----------------------------------|-------------------|
| C1-13               | AHHAADAHH                | 50 (100)                         | 12-21             |
| 3A4                 | AHHAHHA                  | 50 (100.0)                       | 11-18             |
| N7                  | DAHHAADAHHA              | 50 (100)                         | 3-8               |
| 2G12-1C12           | DAHHAADAHH               | 50 (100)                         | 2-8               |
| A6-4                | HATDAHH                  | 50 (100)                         | 3-6               |
| PTL-3               | YAHHAHHA                 | 50 (100)                         | 1-4               |
| S2-5                | AHHASDAHHA               | 48 (96.0)                        | 0-3               |
| 1E1-A9              | AHHAHHV                  | 47 (94.0)                        | 0-9               |
| TC-10               | TDAHHAADAHHAADA          | 42 (84.0)                        | 0-2               |
| C2-3                | HAHHAHAADAHH             | 16 (32.0)                        | 0-2               |
| Genway              | AYAHHAHHAAY              | 0 (0.0)                          | 0                 |
Figure 1

Structural organization and relatedness between the Ghanaian PfHRP2 sequences and homologous sequences from other regions. (a) Schematic diagram of the structural organization of PfHRP2 amino acid repeat types in Ghana. The solid line represents semi-conserved amino acid repeat motif. The short dashes represent partial amino acid repeat motif. (b) Cladogram showing the relatedness between the Ghanaian PfHRP2 sequences and homologous sequences from other regions.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Additional file 1.docx